Foolish End Users, Tricky Integrators - What To Do?

I've seen this sad story play out far too many times. Take a foolish end user, someone both naive and hopeful enough to believe that something impossible works. Combine that with an unscrupulous integrator who pushes science fiction solutions to differentiate himself from the pack and win the deal.

The end user organization ultimately loses when the solution does not work. Good...

*** **** **** ** *** ******* *** ****, ** *****, thinks **** **** **** *** ** **** *** ***** ****** as *** *********.

*** **** **** * ******* *** ***? **** ** *** think *** ** **** ** ******** ****?

**** ** ********* ********* *********, **** ** *** ** *** objectives - ** **** ******* ** ** ***** **** *** broader ****** ** ********** *** ******* ******. ************, ** ***** start ********* **** ********* *********** ** *** ******* *** **** community ** **** '*******' *** ***** ** ***** ** ************, properly ******* ***********. **** **** *** ** **? **** **** do *** **** ** *** ****?

Login to read this IPVM discussion.
Why do I need to log in?
IPVM conducts unique testing and research funded by member's payments enabling us to offer the most independent, accurate and in-depth information.

**** ***** ** ****** ** **** ******** ** ******* ** end ****'* ********** ****. ** **** ******** ** ***** ** price **** **** ***********, *** *** *** ********, **** ** such ******** **** *** ****. ***** ******** ******** *** ***** is ****** ** **********' ****. *** ** *** **** ** will ** ***** ******* ** *** ******* ***'* ****. **** without ****** **** ************* ****, *** ** *** **** **** passing ******* *** ****** ** *** ******* (***** ********), *** specific ******* ******** ** *** **** ** *** ********* **** be ******** ** ***** ******** ** ***** *********, *** **** them *** **************** **** ** ****. ** * ****...

***********, ****** *** *** ********. ** ****** *** ***** **** of *** *****.

**** *** *****, **** ***** *******, **** ***** ***** ******* on ******* ******* *******.

***** *** *****, **** ***** *******, **** ** '***** **** and ***** *******' ****** ******* **** *** **********, **** ** meet ******** ***** *** **** ****** ** ***** ******. **** raises *** ******** - **** ** ** ** ** **** scenario?

*** **** *** ** ** **** *** ****** ** ********* the ******** ***** ** ***** *********** **** ***, *** ** you ****** **********, **** ***** ** *******...*****! ***'* *** ** by ***...

* **** ***** **** * ******'* ********** ** *** **** where *** ********** ********* * ****** ** ******** ********* **** were ****** **** ****** ** ******** ******** ****. ***** *** project ****** ** ********. * ***** **** *** ********** *** admitted **** **** ****** ** **** *** ****** ** ******* new ********* ****** **** **** *** ****. * ** *** sure **** ***** **** ******** * **** ******* *** *** client ** *** ********* *********** ** ** *** ***** *******. There ***** ** ** * ******* ******* *** ******** *** proven ********. ** ************* **** ** ** **** ** ***** new ************ ** * **** ***** ***********?

******, ********* ******* *** ********.

* **** ******* ******* **** ***********. ** **** **** *** ocassion, * **** ****** **** * ********** *** ****'* * new ******* **** ** *** ******* ****** *** *** ******* when ** ***** **** *** (*.*., "**'* ********* *** * months **** ***"). ****'* ********* *** ***** ** * **** amount ** ****.

*** ***, "** ************* **** ** ** **** ** ***** *** ************ in * **** ***** ***********?"

********** *** *** ******* ******** ** "*** ************* ********* ** prove ***** *** ************ **** ** * **** ***** ***********?" Unfortunately, **** ** **** *** ***. ***** ** ****** ** gain *** * *** ** **** ** *** ********** ** demonstrated ** ****** ********. *** ****, ****** ** **** ** potential **** ** ** ******* ** ****** *******.

**** *****, *** ******** * ****** ** **** ********* *** purchased ** ***-******** *************, **** ***** ** ***********. ******* **** science ******* *** *********** ************ **** **** ** ******** *****.

*******, * ***** **** ********* *** ***** *** **** ****** than ****** ** ******** ****** ********. *******, ** ***** **** some ****, *** ** ** **** ********* ** **** **********.

**** * *** *** ********** ***** “******* *** *****, ****** Integrators - **** ** **?”, ** ***** ******* ***, “***! Finally * ****** ***** *********** ****’* ***** ** *** ******.” Wrong! ** **** * **** * ******** ****** *** ********** bashing *******.

**** ****'* *********, ***** ********** *********** **** ** ******* *** scorn, ********** ** **** ** **** **** ** ***** ********* as ******* ** ***** ** **** *** **** ****** ** themselves, "***! **** *** ****. *'** ***** ** **** *****." In ******* ******, *** ******** *********** ****** **** ********* ***, or ** ** **** * ****** ** * *** *** apples ******* *** ***** *****?

*********,

*** ****** **********

****** **********, ** *** *** **** ****** *** *** ***********. In ** **********, *********** **** ** *** ** *** **** of ******* (**** **** ***** ** ********* **********) ***** *********** tend ** *** ** *** **** ** ****** (***'* *** in **** ******* *** ******* **** ** **** ** **** will ****).

* ***** **’* ********* **** **** *********** *** *********** ** better ******* *** *** ***** ** ****** ** **** *** realistic ************ *** ***** ******** *******. *******, **** ****** ** a *********** ****** (**** ********* ** *** **** **** ***** to ** ********). ** ******, *** ***** ************ *** **** is **** **** **** ** ******* ********** ********* **** ********** is ********* *** **** *** ************ *** *********** ***. ** the **** **** ******** ** * **** ********** ******* **** a **** **********, **** *** ***** **** **** ***** *** keep **** ***** ****** (“** **** ******** ****, ** *** person ******** *******.” ***. **:**). **** ****** **** ** *** best ******** ******** *** *** *** ****.

**** *** *** ***** **** ** *****:

*.) *** ** *** ******** *** “****” *********** *** ***********? I ***** ****** **** **** ************* *** ********** **** **** that. **** ** ** **** *** ****** ****** ********** ** the ******** ** *** ***** ******* ** ******** *************, (*** many ***-** ****** **** ***** ***** ** ****? *** **** non-AV ****** **** ***** ***-*?), ** *** ***** ** **** beneficial ** ****** ** ******* ************* ******** ************* ******** **** other. * ****** ******* ** ****, ************* *********** *** *********** can **** ******** *** ********* ** *** ***** *** ********.

*.) *** *** *** *** ************* ** **** ******* *** users’ ***** **** ******* *******, (***** ******* **** *** ******* end **** *** *** ****** **********)? ****’* * ***** ****** battle. * ******* **** *** ****** ** **, *** ***’* envy *** *** **. **********, ************* *** ***** ** ******** to **** ******** ********* ****** ** **** ** ***** ** no *********** ******** ** ***** ** (“********” ******* **** ******). Calling **** *** ** ********** * *****. *******/********* **** ** also **** ********** ** **** ******* **** ******* ** ************* security ************* ** *********** **** *** *****, “**, ****’* ********* BS. ** ***’* ** ****.” (** ******, ** *****’* **** when ******* ************* **** ** ****** ****-**** ********* ***** * small *** ***** ***** ** ***********.)

**** (*********) ******,

*** ****** **********

"** ******, ** *****’* **** **** ******* ************* **** ** almost ****-**** ********* ***** * ***** *** ***** ***** ** integrators."

***** ** ******* ***** ****** *****, *****? ;-)

**** *** ****, *** **** ** ***** *** **** ** that ********.